MicroRNA test for testicular cancer diagnosis
Part of Cancer, Hormones & metabolism, Kidney & urinary clinical trials.
This study looks at tiny genetic signals called microRNAs to see if they can help identify or track testicular cancer. It may help doctors recognize testicular cancer more accurately and decide what to do next.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are being evaluated for testicular cancer and are scheduled for orchiectomy (surgery to remove the testicle)
- Your doctors have diagnosed testicular germ cell cancer
- You are between 18 and 70 years old
- You can understand the study and sign consent
- You do not have another active cancer at the same time, except testicular cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether levels of bile acids (substances made by your liver) can help doctors understand how testicular germ cell tumors grow and how they respond to treatment. It may help improve future care for people with this type of cancer.
This study looks at tiny molecules called microRNAs in the blood of people with either small testicular tumors (less than 2 cm) or leftover lymph node masses after chemotherapy for testicular cancer. The goal is to see if these microRNAs can help guide treatment decisions.
This trial tests whether a blood test called miRNA-371 can detect active germ cell tumors in patients who have had surgery or are being watched. It may help guide treatment decisions without needing extra biopsies or scans.
This study is looking at a new marker called miRNA371 in people newly diagnosed with germ cell tumors. The goal is to see if it can help predict relapse and guide treatment decisions.
This study is looking for a simple blood test to help diagnose colorectal cancer earlier. Researchers want to see if certain molecules in the blood can accurately tell who has colorectal cancer and who doesn't.
This study looks at tiny molecules in your body (microRNA) to help doctors better diagnose pancreatic cancer, predict how it may progress, and understand how it responds to treatment. It may help guide more personalized care in the future.
Hear when a new Seminoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.